Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19

Little is known about cardiovascular safety profiles for monoclonal antibody products that received the FDA Emergency Use Authorization for COVID-19. In this study, data from the FDA Adverse Event Reporting System from the first quarter of 2020 to the second quarter of 2022 were used to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jingrui, Jing, Fuyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782649/
https://www.ncbi.nlm.nih.gov/pubmed/36558922
http://dx.doi.org/10.3390/ph15121472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782649/
https://www.ncbi.nlm.nih.gov/pubmed/36558922
http://dx.doi.org/10.3390/ph15121472

Ejemplares similares